Treatment with the angiotensin-converting enzyme inhibitor (ACE) ramipril resulted in significantly lower mortality in hospital compared with no treatment with other generic ACE inhibitors among a large cohort of patients with ST-elevation acute myocardial infarction.
The prospective multi-centre Maximal Individual Therapy of Acute Myocardial Infarction PLUS registry (MITRA PLUS) study assessed the impact of ramipril treatment compared with other angiotensin-converting enzyme inhibitors on clinical outcome in unselected patients. The study was directed by Harm Wienbergen, MD, Herzzentrum Ludwigshafen, and collaborators at Klinikum im Friedrichshain, Berlin, and the Robert-Koch-Krankenhaus, Gehrden, Germany.
Among 14,608 consecutive patients with ST-elevation acute myocardial infarction, 4.7 percent received acute therapy with ramipril, 39.0 percent received other ACE inhibitor therapy, and 56.3 percent received no ACE inhibitor therapy.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!